Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Panobinostat - Biodexa Pharmaceuticals

Next Previous
Drug Profile

Panobinostat - Biodexa Pharmaceuticals

Alternative Names: BDX-110; MTX 110

Latest Information Update: 10 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Midatech
  • Developer Biodexa Pharmaceuticals
  • Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diffuse intrinsic pontine glioma
  • Phase I Glioblastoma
  • Phase 0 Medulloblastoma

Most Recent Events

  • 04 Oct 2024 Efficacy data from a phase I in Glioblastoma released by Biodexa Pharmaceuticals
  • 10 Sep 2024 Biodexa Pharmaceuticals terminates phase I MAGIC-G1 trial in Glioblastoma (Recurrent, Monotherapy, Combination therapy) in USA (Intratumoural), due to strategic decisions (NCT05324501)
  • 02 Jul 2024 Adverse events and efficacy data from a phase I trial in Diffuse intrinsic pontine glioma released by Biodexa Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top